Saturday 17 October 2026 Export PCRX’s income statement to Excel — free account

Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

36.35 0.02 +0.06%

Follow PCRX

Alert me

Market cap: $1.5B
P/E: 104×
Fwd P/E: 33.7×
Dividend yield: —
F-score: 8/9
Altman Z: 2.02
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.75

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	1	2	2	2	—	2	—	1	—	1

Insider Ownership 3.25%

Capital & Financial Ratios $m

Market Cap 1,450.00

Revenue 746.16

Net Income 14.64

Free Cash Flow 179.52

Net Debt 112.09

Current Ratio 5.04

Debt/Equity 0.54

P/E ratio 103.86

Fwd P/E 33.70

P/S ratio 1.92

P/B ratio 2.13

Past 5Y EPS Growth (45.51%)

This Y EPS Growth 9.28%

Next Y EPS Growth 19.44%

Next Y revenue growth 3.84%

Next 5Y EPS Growth 20.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 61.16%

10-year low 10-year high

P/S against its own 10 years 22.59%

10-year low 10-year high

P/B against its own 10 years 29.82%

10-year low 10-year high

EV/Sales against its own 10 years 23.59%

10-year low 10-year high

EV/FCF against its own 10 years 19.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	279	485	238	251
Receivables	106	113	124	132
Inventory	104	125	153	135
Other	—	—	—	67
	510	745	548	615

	2023	2024	2025	Q'26
Payables	16	19	15	18
ST’ Debt	9	202	—	—
Other	—	—	—	1
	97	310	121	122

Compound Annual Growth %

	10y	5y	3y
Sales	11.30%	11.07%	2.89%
Cash Flow	18.42%	14.56%	1.52%
Earnings	14.25%	(45.44%)	(23.82%)
Book Value	12.24%	2.26%	(3.65%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	177	192	—	—	—
’25	169	181	180	197	726
’24	167	178	169	187	701
’23	160	169	164	181	675
’22	158	169	167	172	667
’21	119	136	128	159	542
’20	106	76	117	131	430

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	26	57	—	—	—
’25	35	12	61	44	152
’24	49	53	54	33	189
’23	19	43	44	48	155
’22	31	30	43	42	145
’21	12	30	60	23	126
’20	6	(16)	40	47	77

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	23	56	—	—	—
’25	27	9	57	43	137
’24	46	52	50	31	179
’23	13	40	41	46	139
’22	23	18	37	37	115
’21	(1)	20	47	14	80
’20	(1)	(25)	32	32	39

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.07	0.12	—	—	—
’25	0.10	(0.11)	0.12	0.04	0.16
’24	0.19	0.39	(3.11)	0.34	(2.15)
’23	(0.43)	0.51	0.23	0.50	0.89
’22	0.15	0.40	(0.02)	(0.22)	0.34
’21	0.23	0.42	0.39	(0.12)	0.92
’20	0.19	(0.17)	2.94	0.32	3.33

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	29.95	29.81	26.95	34.64	27.46	45.05	37.69	25.93	11.16	18.17	Analyst estimates 2026–2028 Powerpack
	High	76.75	58.95	55.00	49.50	68.08	80.00	82.16	48.60	35.95	27.64
People
People	Employees	503	489	518	606	624	697	715	712	790	829
	Revenue/emp, $m	0.55	0.59	0.65	0.69	0.69	0.78	0.93	0.95	0.89	0.88
Income, $m
Income, $m	Revenue	276	287	337	421	430	542	667	675	701	726
	Gross margin, %	60.16	69.33	74.25	74.65	72.69	74.10	70.11	72.64	75.69	79.39
	EBT	(38)	(42)	0	(11)	20	56	13	62	(63)	17
	EBT margin, %	(13.69)	(14.82)	(0.13)	(2.55)	4.68	10.42	1.99	9.14	(9.00)	2.32
	Net income	(38)	(43)	0	(11)	146	42	16	42	(100)	7
	Depreciation	17	26	28	35	40	54	99	75	75	89
Per share, $
Per share, $	Revenue	7.42	7.20	8.24	10.14	10.07	12.23	14.65	14.60	15.16	16.30
	Earnings	(1.02)	(1.07)	(0.01)	(0.27)	3.41	0.95	0.35	0.91	(2.15)	0.16
	Cash flow	0.90	0.45	1.19	1.70	1.81	2.84	3.19	3.35	4.10	3.41
	Capex	(0.66)	(0.48)	(0.35)	(0.24)	(0.89)	(1.04)	(0.66)	(0.33)	(0.23)	(0.34)
	Free cash flow	0.23	(0.04)	0.84	1.45	0.92	1.80	2.53	3.02	3.87	3.07
	Book value	5.88	7.02	7.85	8.55	14.52	16.50	17.03	18.83	16.83	15.55
	Shares, m	37	40	41	42	43	44	46	46	46	45
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	17.70	63.34	109.50	35.56	0.00	172.53
	P/S	4.68	6.43	5.22	4.47	5.94	4.92	2.65	2.19	1.24	1.59
	P/B	5.91	6.59	5.48	5.30	4.12	3.65	2.28	1.70	1.12	1.66
	EV/Sales	4.45	6.31	4.94	4.51	5.82	5.00	3.25	2.55	1.39	2.05
	EV/FCF	140.68	(1,220.69)	48.53	31.47	63.77	33.88	18.84	12.35	5.44	10.90
Cash, $m
Cash, $m	Operating cash flow	33	18	49	71	77	126	145	155	189	152
	Capex	(25)	(19)	(15)	(10)	(38)	(46)	(30)	(15)	(11)	(15)
	Free cash flow	9	(1)	34	60	39	80	115	139	179	137
Balance, $m
Balance, $m	Working capital	198	335	417	301	398	345	351	413	435	427
	Total debt	109	276	291	311	470	699	689	522	585	372
	Net debt	(64)	(35)	(93)	19	(52)	42	401	244	101	134
	Shareholders’ equity	219	279	321	355	620	730	775	870	778	693
Returns, %
Returns, %	ROA	(9.74)	(8.36)	(0.07)	(1.45)	13.82	2.51	0.85	2.58	(6.37)	0.50
	ROIC	(12.90)	(6.38)	4.36	1.75	5.10	7.27	3.19	4.92	(5.22)	1.45
	ROE	(17.35)	(17.10)	(0.16)	(3.26)	29.86	6.22	2.11	5.10	(12.08)	0.96

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%	Compare
ETON Eton Pharmaceuticals, Inc.	$1.5B	107×	40.3×	+98.59% (above 0%: growing)	n/m	−8.78% (below 0%: shrinking)	67.61%	34.04%	Compare
PCRX Pacira BioSciences, Inc.	$1.5B	104×	33.7×	+6.24% (above 0%: growing)	n/m	+502.51% (above 0%: growing)	77.05%	2.22%
CRON Cronos Group Inc.	$1.2B	16.1×	32.2×	+58.44% (above 0%: growing)	n/m	+2,279.22% (above 0%: growing)	53.67%	13.97%	Compare
AMPH Amphastar Pharmaceuticals, Inc.	$1.1B	14.9×	14.7×	+5.44% (above 0%: growing)	+4.55% (above 0%: growing)	+87.61% (above 0%: growing)	50.83%	21.60%	Compare
HROW Harrow, Inc.	$1.1B	— (loss-making)	134×	+10.85% (above 0%: growing)	n/m	−838.78% (below 0%: shrinking)	71.27%	(15.58%)	Compare
Median of peers	$1.5B	15.8×	32.2×	+27.31%	+111.58%	+39.42%	64.98%	14.59%

All 86 Drug Manufacturers Specialty & Generic stocks →

Pacira BioSciences, Inc. (PCRX) key facts

Strength: Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
Pacira BioSciences, Inc. (PCRX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PCRX traded at $36.35, a market capitalization of $1.5 billion.
Return on equity was 0.96% and debt-to-equity 0.54.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 2.02 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.